Day: June 23, 2020

The Pandemic’s Mental Toll: More Ripple Than Tsunami

The evidence from recent surveys asking people about their emotions during the pandemic is not convincing one way or the other either, experts said. One reason is that these surveys often do not make distinctions between people in the thick of the action — front-line workers, in this case — and everyone else. Millions of Americans have been juggling Zoom cocktail hours with Netflix binges: a time-management challenge, perhaps, but not one that has been linked to prolonged trauma.

Moreover, psychological distress usually takes time to consolidate into the kind of persistent condition that drives people to seek treatment, revealing a diagnosable psychiatric disorder. Generalized anxiety disorder, for instance, is defined in part by excessive anxiety for at least six months. Post-traumatic stress requires, first, experiencing a life-threatening event, either personally; through a loved one; or up close, like witnessing deaths in an intensive care unit. Nightmares and other reverberations

Read More

Public Health Experts Reject President’s View of Fading Pandemic

Public health experts warned on Sunday that the coronavirus pandemic is not going away anytime soon. They directly contradicted President Trump’s promise that the disease that has infected more than two million Americans would “fade away” and his remarks that disparaged the value of evidence from coronavirus tests.

A day after Mr. Trump told a largely maskless audience at an indoor rally in Tulsa, Okla., that he had asked to “slow down the testing” because it inevitably increased the number of confirmed coronavirus cases, infectious disease experts countered that the latest rise of infections in the United States is real, the country’s response to the pandemic is not working and rallies like the president’s risk becoming major spreading events.

Dr. Tom Inglesby, the director of the Center for Health Security at the Johns Hopkins Bloomberg School of Public Health, said on “Fox News Sunday” that the spikes in confirmed cases

Read More

Gilead to Test a Version of Remdesivir That Can Be Inhaled

The American biopharmaceutical company Gilead Sciences will soon start trials of an inhalable version of remdesivir, an antiviral drug that has shown promise as a therapeutic against the coronavirus in early trials, according to a statement released Monday.

Remdesivir is currently given intravenously, which restricts its use to hospital settings. “That’s been the limitation” with this drug, said Dr. Mangala Narasimhan, a pulmonologist and regional director of critical care medicine at Northwell Health.

Gilead’s inhalable version of the treatment would be administered through a nebulizer, a device that sends a mist of therapeutic liquid into the airway and is often used by asthma patients. Some nebulizers are portable; Gilead scientists hope that a more convenient treatment would be used by patients at various stages of infection.

Nebulizers “are commonly available” compared with IV equipment, said Angela Rasmussen, a virologist at Columbia University. “Pretty much every outpatient urgent care clinic has

Read More